12:00 AM
May 31, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Xenical orlistat regulatory update

FDA revised the label for weight-loss drug orlistat to include a warning about rare reports of severe liver injury after an agency review identified 13 total cases, including 2 deaths and 3 liver transplantations, that occurred between 1999 and 2009. Orlistat is marketed for prescription use as...

Read the full 212 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >